CClinicalTrials.gg
CompletedNCT01096264ULTRAFASTECHOUpdated Mar 9, 2015

Non-Invasive Quantitative Imaging of Human Local Arterial Wall Elasticity Using Supersonic Shear Imaging

An interventional study of SSI and SphygmoCor® evaluations in Healthy Volunteers and Vascular Ehlers Danlos Syndrome, sponsored by French Cardiology Society. Completed at 1 site in France. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-03-09.

Sponsored by French Cardiology Society · Not applicable and Interventional

Phase
Not applicable
Study type
Interventional
Enrollment
145
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

Arterial stiffness is associated with increased risk of cardiovascular events and death.

Most of existing technique need dedicated device for arterial stiffness evaluation and indirect calculation of intra arterial pressure. Supersonic Shear Imaging (SSI) is a novel non-invasive technique based on remote palpation of biological tissues that can image with very high temporal resolution (up to 10,000 images/s) and quantify the local viscoelastic properties of tissues. The investigators goal was to apply this SSI technique for arterial stiffness evaluation and local pulse wave velocity (PWV) calculation.

As a first step, the primary goal of this study is to establish normal values of local pulse wave velocity and arterial stiffness (carotid and femoral) by SSI on hundred healthy volunteers.

Read the detailed description

Provide a more extensive description, if desired. Avoid duplication of information to be recorded elsewhere, such as eligibility criteria or outcome measures.

02

Conditions studied

  • Healthy Volunteers
  • Vascular Ehlers Danlos Syndrome

Browse trials for

Keywords

  • Arterial stiffness
  • Pulse wave velocity
  • Ultrafastecho
  • Supersonic shear imaging
03

In context

Ehlers-Danlos Syndrome

75 studies on the registry are indexed under Ehlers-Danlos Syndrome; 25 are open to participants now.

This study's enrollment of 145 is above the median of 52 across 42 interventional studies indexed under Ehlers-Danlos Syndrome.

Browse Ehlers-Danlos Syndrome studies →

Lead sponsor

French Cardiology Society is the lead sponsor of 84 studies on the registry; 15 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion criteria for Healthy Volunteers

  • Healthy volunteers between 18 and 70 years old of two sexes.
  • Caucasian origin
  • No tobacco or stopped for more than 5 years
  • BMI between 18 and 30 kg/m2.
  • Blood pressure after 5 minutes of rest \< 140 and 90 mmHg.
  • Biological test (haematological biochemistry test in blood , urine test and toxicology tests are all normal) ECG, Blood pressure and Heart rhythm normal.
  • All volunteers received information on the research and signed the consent form.
  • Health system protection required

Inclusion criteria for patient :

  • Age between, 18 et 70 years old for the two sexes
  • Presence of two major criteria of Villefranche classification (Am J Med Genet 1998 ;77:31-7) and/or heterozygote pathogen mutation of COL3A1 gene.
  • At least 4cm long normal arterial segment (carotid or femoral) analyzed by mode B echograph.
  • All patient received information on the research and signed the consent form.
  • Health system protection required

General Exclusion Criteria :

  • Pregnancy
  • Echograph gel allergy
  • Local Artery disease (dissection or thrombosis)
  • Arrhythmia
  • No health insurance coverage
  • Incapacity or refused to sign the consent form

Exclusion criteria for Healthy volunteers

  • Acute or Chronic Systemic disease (atherosclerosis)
  • Alcohol abuse or drug abuse (cocaine,cannabis,etc..)
  • Active or past tobacco
  • Hypercholesterolemia (LDLc >1.09 g/l)
  • Exclusion period according to the national record for volunteer of clinical trial.

Exclusion criteria for Patients

  • No intact (carotid or femoral) segment for SSI analysis
  • AT2 inhibitors or Beta blockers treatment will be notified but are not considered as exclusion criteria.
05

Study design

Phase
Not applicable
Allocation
Non-randomized
Intervention model
Factorial assignment
Masking
None (open label)
Enrollment
145 participants (actual)

Study arms

  • Other
    Healthy volunteer

    Healthy volunteer undergoing two imagery evaluation : * SSI technique for local PWV and arterial stiffness evaluation * SphygmoCor® for aortic PWV.

    Other: SSI and SphygmoCor® evaluations

  • Other
    vEDS patients

    vEDS patients undergoing two imagery evaluations: * SSI technique for local PWV and arterial stiffness evaluation * SphygmoCor® for aortic PWV.

    Other: SSI and SphygmoCor® evaluations

Interventions

  • OtherSSI and SphygmoCor® evaluations

    * SSI evaluation need Aixplorer vascular ultrasound machine (available in our department) with 8 MHz linear array probe applied on the carotid and femoral artery. * SphygmoCor® evaluation used pressure captors on carotid and femoral sites to record the intra-arterial pressure wave time delay after QRS wave. After distance calculation between the two sites, Aortic PWV can be derived.

06

What researchers measure

Primary outcomes

  1. Normal Values by SSI

    Normal Values by SSI of local PWV and arterial wall stiffness(carotid and femoral).

    Time frame: day one

Secondary outcomes

  1. repeatability of the "primary outcome measure"

    Evaluation of the repeatability of the "primary outcome measure" on 100 healthy volunteers and 30 patients with Vascular Ehlers Danlos Syndrome (vEDS).

    Time frame: Day one

  2. Comparison between 2 populations of values by SSI

    Comparison between healthy volunteers and vEDS patients for PWV and arterial stiffness evaluated by SSI.

    Time frame: Day one

  3. Comparison of values between SSI and standard gold

    Concordance evaluation between PWV calculated by SSI and Aortic Pulse wave velocity calculated by ShygmoCor®

    Time frame: Day one

07

Study locations

1 site
  • CIC - Hôpital Européen Georges Pompidou
    Paris, 75015, France
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 9, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01096264
Lead sponsor
French Cardiology Society
Collaborators
National Research Agency, France, SOCIETE FRANCAISE DE MEDECINE VASCULAIRE
First posted
Mar 31, 2010
Start date
Mar 2010
Primary completion
Mar 2011
Completion
Mar 2011
Last update
Mar 9, 2015

Study contacts

Emmanuel Messas, MD
principal investigator · Hôpital Européen Georges-Pompidou
Anne Blanchard, MD
study chair · Hôpital Européen Georges-Pompidou
Joseph Emmerich, MD, PhD
study chair · Hôpital Européen Georges-Pompidou
Xavier Jeunemaitre, MD, PhD
study chair · Hôpital Européen Georges-Pompidou
Michael Franck, MD
study chair · Hôpital Européen Georges-Pompidou
Olivier Steinchen, MD
study chair · Hôpital Européen Georges-Pompidou
Michel Azizi, MD, PhD
study chair · Hôpital Européen Georges-Pompidou

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion